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Abstract
Background: Nephrotic syndrome represents a condition in pediatric nephrology typified by a relapsing and remitting
course, proteinuria and the presence of edema. The PROMIS measures have previously been studied and validated in
cross-sectional studies of children with nephrotic syndrome. This study was designed to longitudinally validate the
PROMIS measures in pediatric nephrotic syndrome.
Methods: One hundred twenty seven children with nephrotic syndrome between the ages of 8 and 17 years participated in
this prospective cohort study. Patients completed a baseline assessment while their nephrotic syndrome was active, a follow-
up assessment at the time of their first complete proteinuria remission or study month 3 if no remission occurred, and a final
assessment at study month 12. Participants completed six PROMIS measures (Mobility, Fatigue, Pain Interference, Depressive
Symptoms, Anxiety, and Peer Relationships), the PedsQL version 4.0, and two global assessment of change items.
Results: Disease status was classified at each assessment: nephrotic syndrome active in 100% at baseline, 33% at month 3,
and 46% at month 12. The PROMIS domains of Mobility, Fatigue, Pain Interference, Depressive Symptoms, and Anxiety each
showed a significant overall improvement over time (p < 0.001). When the PROMIS measures were compared to the patients’
global assessment of change, the domains of Mobility, Fatigue, Pain Interference, and Anxiety consistently changed in an
expected fashion. With the exception of Pain Interference, change in PROMIS domain scores did not correlate with changes
in disease activity. PROMIS domain scores were moderately correlated with analogous PedsQL domain scores.
Conclusion: This study demonstrates that the PROMIS Mobility, Fatigue, Pain Interference, and Anxiety domains are sensitive
to self-reported changes in disease and overall health status over time in children with nephrotic syndrome. The lack of
significant anchoring to clinically defined nephrotic syndrome disease active and remission status may highlight an
opportunity to improve the measurement of HRQOL in children with nephrotic syndrome through the development
of a nephrotic syndrome disease-specific HRQOL measure.
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Background
Nephrotic syndrome is a challenging disease typified by
a complex disease spectrum, including a single episode,
relapsing and remitting disease, and persistent progres-
sive disease resulting in end stage kidney disease in the
worst cases [1]. Nephrotic syndrome can result in
multiple complications, frequent hospitalizations, and
upheaval of children’s day to day lives. Furthermore,
nephrotic syndrome frequently can become a chronic
disease that continues throughout the critical years of a
child’s development and persists into adulthood.
Although we have made significant improvements in
clinical care, these children continue to experience diffi-
culties in functioning. In order to better understand
these functional limitations, longitudinal assessments of
health-related quality of life (HRQOL) are imperative.
HRQOL is impacted in nephrotic syndrome by symp-
toms related to the disease (edema), medications (e.g.,
corticosteroids, calcineurin inhibitors), and the unpre-
dictable relapsing-remitting nature of the disease [2, 3].
Although cross-sectional evaluations have shown that
NS adversely impacts HRQOL in physical, social, and
emotional domains [2–4], there is an absence of pub-
lished data about the longitudinal trends in HRQOL in
this population. The NIH Sponsored Patient-Reported
Outcomes Measurement Information System® (PROMIS®)
has expanded our ability to measure and describe the
HRQOL in children with chronic disease by creating mea-
sures that are efficient, precise, and valid across a variety
of diseases to assess patient-reported outcomes (PROs)
(www.HealthMeasures.net) [5–9]. Pediatric nephrotic syn-
drome has been incorporated as one of the exemplar
chronic conditions in the initial PROMIS I and PROMIS
II validation studies [10]. The initial PROMIS validation
work in pediatric nephrotic syndrome showed the mea-
sures were associated with disease status. Specifically, chil-
dren with active nephrotic syndrome (i.e., presence of
edema) had more Fatigue, Pain Interference, and Anxiety
and less Mobility than children with inactive disease [3].
In addition, work has shown that children with prevalent
disease experience more Pain Interference and are less sat-
isfied with their Peer Relationships than children with in-
cident disease [11]. Furthermore, our previous work has
shown that the PROMIS measures provide complimentary
results to a legacy measure, PedsQL™ 4.0 Generic Scales
(PedsQL), with important differences that likely reflect
differences in measure content [12].
A critical next step in the validation process is a longi-
tudinal assessment of the ability of the PROMIS mea-
sures to detect change over time. In order to address
this need, this study was designed to: (1) comprehen-
sively describe the longitudinal HRQOL experience in
pediatric nephrotic syndrome, (2) evaluate the respon-
siveness of PROMIS measures to self-reported global
assessments of change, (3) evaluate the responsiveness
of PROMIS to changes in disease state, and to (4) assess
the consistency of the findings of the PROMIS and a
legacy instrument (PedsQL).
Methods
Study design and participants
The PROMIS II nephrotic syndrome longitudinal cohort
study enrolled children with active nephrotic syndrome
from 14 participating centers (12 from the Midwest
Pediatric Nephrology Consortium (United States and
Canada) and 2 additional centers in the United States).
Each site obtained institutional IRB approval. Parents
and children gave informed consent and assent respect-
ively prior to enrollment in this study.
The PROMIS II nephrotic syndrome cohort included
children 8–17 years. Children with active nephrotic syn-
drome defined as the presence of nephrotic range pro-
teinuria (>2+ urinalysis and edema or urine protein/
creatinine ratio (UPC) >2 g/g) were eligible. Exclusion
criteria included co-existing medical, psychiatric, or cog-
nitive impairments that would prevent the patient from
answering the computer administered questionnaire or
the inability to speak and read English.
The longitudinal study design included three study
visits. Patients completed a baseline assessment while
their nephrotic syndrome was active. Patients completed
an event assessment (event visit) when: 1) they reached
complete remission or 2) three months after their base-
line visit if remission did not occur. This event visit was
conducted on-line. Finally, all patients completed a third
visit 12 months after their baseline visit. While all pa-
tients were active at baseline, patients could either have
active disease or be in remission at their two follow-up
visits. Remission was defined as normalization of urinary
protein excretion and complete resolution of edema.
Data on symptom burden, past medical history and
other health conditions, demographic information,
medication, and health care utilization were collected at
each visit. A physical evaluation measuring edema, blood
pressure, and body size measurements was done at
baseline and at month 12. Laboratory data, such as
urine protein: creatinine ratio (UPC) and eGFR, were
also collected at baseline and month 12, but not at
the event visit.
Collection of PRO data
The PROMIS Pediatric measures included PROMIS
measures of physical health (Mobility, Fatigue, Pain
Interference), mental health (Depressive Symptoms and
Anxiety) and social health (Peer Relationships). We used
the PROMIS Assessment Center web-based interface
(www.assessmentcenter.net) to administer computer-
adaptive testing (CAT) questionnaires. Each PROMIS
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question used the context statement “In the past 7 days.”
Responses included 5 options ranging from “never” to
“almost always” in the majority of domains and from
“with no trouble” to “not able to do” for the Mobility
measure. Each PROMIS Pediatric measure generates a
T-score (mean = 50, standard deviation (SD) = 10 in the
calibration population) [6]. Higher scores indicate higher
levels of the trait that is being measured (i.e., higher
scores signify worse Depression, Anxiety, Fatigue,
and Pain Interference, and better functioning for
Mobility and Peer Relationships). Administration
time for all PROMIS measures using CAT was ap-
proximately six minutes.
The PedsQL is a legacy instrument designed to meas-
ure HRQOL in children. The instrument measures phys-
ical, emotional, social, school, and overall functioning.
This instrument has been evaluated in healthy children
and in multiple pediatric chronic conditions including
chronic kidney disease [13]. The PedsQL asks partici-
pants to review statements and rate the degree that the
subject has experienced that symptom in the past week.
The domain scores result from the summation of prob-
lem frequency within each domain. Scores range from 0
to 100 with higher scores indicating better function.
Mean scores in the general population range from 78 to
87 depending on the domain (standard deviations range
from 13 to 19 [12]. Administration time was approxi-
mately ten minutes.
In addition to standardized assessments of PROs, pa-
tients were also asked questions to determine their glo-
bal assessment of change for nephrotic syndrome and
for overall health. At the event (post baseline assess-
ment) and month 12 visits, patients were asked “How is
your nephrotic syndrome compared to your last study
visit?,” and “How is your overall health compared to
your last study visit?” each with possible responses of
“Better,” “About the same,” and “Worse.”
Patient clinical classification was assigned at each
study visit as nephrotic syndrome disease remission de-
fined as normalization of urinary protein excretion and
complete resolution of edema. Patients who were not in
a remission were considered to have active disease.
Statistical analysis
Descriptive statistics on key variables of interest were
provided as frequencies and percentages with means and
SD as appropriate. Changes in scores across follow-up
visits were tested using a repeated measures ANOVA
analysis. Statistical significance was tested using F-tests,
and effect sizes were measured using an eta-squared.
Changes in scores for all PRO measures were calcu-
lated by subtracting the patient’s score from their base-
line assessment. These values were then compared
across response categories to the global assessment of
change items with the hypothesis that those reporting
improvements in their nephrotic syndrome or general
health would be more likely to have improvements in
PRO scores. Statistical significance for these compari-
sons was assessed using a repeated measure ANOVA.
Analogous repeated measures ANOVAs were conducted
to test for a difference in PRO scores over time by pro-
teinuric remission status at follow-up. We also tested if
global assessment of change or remission status was as-
sociated with a significant change greater than the pub-
lished Pediatric PROMIS domain score minimally
important difference of 3 [14]. To test this, we examined
if the 95% confidence interval of the mean change for
each group contained the minimally important differ-
ence value of 3 [14].
Finally, changes in PROMIS scores were compared to
changes in PedsQL scores using Pearson correlation
coefficients.
Results
There were 127 patients who completed a baseline visit,
112 with a completed event visit and 90 with a 12-
month follow-up visit. The cohort was relatively equally
distributed by age (8–12 vs. 13–17 years old) and disease
duration (Incident vs. Prevalent). The median days from
baseline to first follow-up in those reaching remission
was 39 (IQR 20, 81) compared to 104 (IQR 89, 120) in
those not reaching remission (p < 0.0001). A total of 75
of 112 participants were in remission at the event visit
and 49 of 90 participates were in remission at the 12-
month visit. Patient demographics and clinical character-
istics of the sample are presented in Table 1. The cohort
at baseline was notable for edema in 76%, immunosup-
pression in 78%, and hospitalized within the last
6 months in 46%.
Table 2 shows the mean scores for the PROMIS and
PedsQL domains at each visit. Over time the HRQOL
scores improved in each of the domains in both instru-
ments. On average, patients had more favorable HRQOL
scores (e.g., more Mobility; less Fatigue) during follow-
up than at baseline. For example, the baseline mean
Mobility score of 46.3 increased to 52.4 at month 12. All
of the PROMIS and PedsQL domains tested changed
significantly over time with the exception of PROMIS
Peer Relationships and PedsQL Social Functioning. The
same pattern was observed when limiting the analyses to
85 patients with PROMIS assessments at all three
study visits. A separate analysis was performed and
noted that change in PROMIS and PedsQL scores did
not differ significantly by race at the event visit or
the 12-month visit.
When the PROMIS scores were compared to the pa-
tients’ global assessment of change in nephrotic syn-
drome at the event visit, PROMIS Mobility, Fatigue,
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Pain Interference, and Anxiety changed in an expected
fashion: patients reporting an improvement in their
nephrotic syndrome showed an improvement in their
PRO (Fig. 1). For example, the 78 participants who re-
ported that their nephrotic syndrome had improved
since their last visit had a mean increase in Mobility of
5.8 points. The 30 participants who indicated their
nephrotic syndrome was “about the same” or “worse” on
average had a mean decrease in Mobility of 0.1 points
(|d| = 0.64). The MID of |3| is indicated on Fig. 1 with a
dotted line. Patients reporting that their nephrotic
syndrome was “better” had an improvement in Mobility,
Fatigue, Pain Interference, and Anxiety at a magnitude
significantly greater than the MID of 3 based on 95%
confidence intervals. For example, as stated above, pa-
tients reporting that their NS was “better” had a mean
increase in mobility of 5.8 points, and the 95% confi-
dence interval for this estimate ranged from 3.6 to 7.9
indicating a statistically significant change of more than
3.0 (one-sample t-test p = 0.007).
Figure 2 contains similar estimates comparing change
in PRO to the patient’s reported change in overall health.
As with the global assessment of nephrotic syndrome,
there were significant differences by global assessment of
overall health and changes of PROMIS Mobility, Fatigue,
Pain Interference, and Anxiety. There was also a signifi-
cant difference in Peer Relationships (|d| = 0.52,
p = 0.02), however, the degree of change in Peer Rela-
tionships for the “better” group was not greater than the
MID of 3.
Figure 3 compares changes in PRO by changes in clinical
disease activity during follow-up. As part of the study de-
sign all patients had active disease at baseline, but disease
activity varied during follow-up visits. While there was a
significant relationship between proteinuria remission at
the event visit and mean change in Peer Relationships score
(p = 0.02 |d| = 0.49), no other domains had a statistically
significant relationship between change in PRO and disease
activity at the event visit. Additionally, those in the remis-
sion group did, on average, improve their Peer Relation-
ships scores by more than the MID of 3.0.
Figure 4 compares changes in PRO by remission status
at month 12. There was a significant difference in
change of Pain Interference scores by remission status
where those achieving a remission had a mean decrease
in Pain Interference of 7.2 points from their active base-
line visit, and those with persistently active disease had a
mean decrease of 1.4 (|d| = 0.33, 0.03). Apart from this
difference in Pain Interference scores, there was no sig-
nificant difference in change in PROMIS scores by re-
mission status at month 12.
Finally, correlations of the changes in PROMIS scores
with the changes in PedsQL scores are displayed in
Table 3. Similar domains had stronger correlations. For
example, PROMIS Mobility and PedsQL Physical Func-
tioning had a correlation of r = 0.60; PROMIS Anxiety
and PedsQL Anxiety had a correlation of r = −0.68 (i.e.,
higher PROMIS Anxiety correlated with worse PedsQL
emotional functioning, as expected). PROMIS Peer Rela-
tionships was not correlated with PedsQL Social
Functioning (r = 0.11). Analogous analyses of the re-
sponsiveness of the PedsQL to changes in global assess-
ment of change and to remission status are found in
Additional file 1 Fig. S1, Additional file 2: Fig. S2,
Additional file 3: Fig. S3 and Additional file 4: Fig. S4.
Table 1 PROMIS II patient characteristics at baseline
N(%), or Mean(std)
Disease duration
Incident, n(%) 60 (47)
Prevalent, n(%) 67 (53)
Age
8–12 years, n(%) 67 (53)
13–17 years, n(%) 60 (47)
Female, n(%) 44 (35)
Race
White, n(%) 65 (52)
Black, n(%) 36 (28)
Asian, n(%) 16 (13)
Other, n(%) 10 (8)
Hispanic or Latino ethnicity, n(%) 10 (8)
Maternal Education
< High School, n(%) 12 (9)
High school, n(%) 46 (36)
2-Year Associate’s Degree, n(%) 16 (13)
4-Year College Degree, n(%) 24 (19)
Graduate Degree, n(%) 7 (6)
Unknown, n(%) 22 (17)
Obese, n(%) 44 (35)
Edema Present, n(%) 96 (76)
Hypertension, n(%) 53 (42)
Number of Symptoms, Mean(std) 4 (3)
Number of Medical Conditions, Mean(std) 1 (1)
Immunosuppressive therapy, n(%) 99 (78)
Emergency Department Visits in last 6
months (≥ 1 visit), n(%)
49 (39)
Hospitalizations in last 6 months (≥ 1 visit), n(%) 58 (46)
Estimated GFR (mL/min/1.73 m2), Mean(std) 113 (48)
Urine Protein:Creatinine, Mean(std) 6.7 (7.1)
Albumin, Mean(std) 2.4 (1.0)
Hemoglobin, Mean(std) 13.3 (2.0)
Number of medications, Mean(std) 3 (3)
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The PedsQL Physical Functioning domain showed the
strongest relationship to global assessment of change in
nephrotic syndrome and overall health (|d| = 0.65 and
0.72 respectively). Remission status at the event visit was
not associated with changes in any of the PedsQL do-
mains. Remission status at the month 12 visit was
associated with greater improvement in PedsQL Phys-
ical, Emotional, and Social functioning.
Discussion
This comprehensive longitudinal study evaluated PRO-
MIS pediatric domains in children with nephrotic
Table 2 PROMIS II HRQOL domain scores at each assessment
Baseline Event visit Month 12
N = 127 N = 112 N = 90
PROMIS Mean(SD) Clinically impaired
N(%)*
Mean(SD) Clinically impaired
N(%)*
Mean(SD) Clinically impaired
N(%)*
F-value p-value η2
Mobility 46.3 (9.2) 31 (25) 50.8 (9.5) 14 (13) 52.4 (9.2) 9 (10) 12.81 <0.001 0.074
Fatigue 49.6 (12.6) 29 (23) 43.4 (12.7) 9 (8) 43.3 (13.4) 11 (12) 9.16 <0.001 0.054
Pain Interference 49.7 (11.1) 24 (20) 44.9 (11.2) 7 (6) 44.7 (10.9) 10 (11) 7.44 <0.001 0.045
Depression 49.7 (9.3) 22 (18) 45.2 (9.9) 8 (7) 46.2 (9.6) 6 (7) 7.04 0.001 0.042
Anxiety 49.4 (10.6) 23 (19) 43.2 (11.5) 11 (10) 44.5 (10.7) 7 (8) 10.64 <0.001 0.062
Peer
Relationships
48.6 (10.6) 23 (19) 50.4 (11.3) 16 (15) 51.7 (10.4) 7 (8) 2.15 0.12 0.013
PedsQL
Physical
functioning
69.3 (22.7) 59 (47) 79.1 (20.8) 29 (27) 81.5 (21.1) 25 (28) 10.04 <0.001 0.059
Emotional
functioning
72.3 (22.1) 61 (48) 80.1 (20.9) 33 (30) 80.5 (20.9) 27 (30) 5.42 0.005 0.032
Social functioning 80.6 (18.0) 25 (20) 84.0 (18.2) 18 (17) 85.2 (18.5) 16 (18) 1.91 0.15 0.012
School
functioning
63.7 (21.2) 38 (35) 76.9 (20.3) 15 (16) 74.7 (21.1) 20 (25) 11.57 <0.001 0.076
Overall 71.0 (17.0) 44 (35) 80.0 (17.1) 21 (19) 80.5 (18.2) 20 (22) 10.91 <0.001 0.064
*>1SD from the mean in the clinically impaired direction. For PROMIS Mobility, and Peer Relationships, a higher score indicates better patient reported
outcomes; for PROMIS Fatigue, Pain Interference, Depression, and Anxiety a higher score indicates worse patient reported outcomes. For all PedsQL
domains, a higher score indicates better patient reported outcomes
Fig. 1 Change in PROMIS scores from baseline to event visit by self-reported Global Assessment of Change in nephrotic syndrome since last study visit. Results are
shown as mean change with 95% confidence intervals. Group Sample sizes: Better =78, About the same=25, Worse=5. Minimally Important Difference (MID)
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syndrome for the purposes of validation. The PROMIS
scores in this disease group were assessed longitudinally
and compared to three types of anchor measurements
(1) self-reported global assessment of change, (2) a clin-
ical marker of disease status, and (3) a legacy HRQOL
instrument. We demonstrated that the Mobility, Fatigue,
Pain Interference, and Anxiety domains were significantly
associated with both the self-reported global assessments
of change, and the legacy HRQOL instrument. However,
we did not find that these domains were associated with a
clinical marker of disease status. Overall, we recom-
mend this subset of PROMIS domains for use in
measuring HRQOL over time in pediatric patients
with nephrotic syndrome.
Fig. 2 Change in PROMIS scores from baseline to event visit by Global Assessment of Change in overall health since last study visit. Results are
shown as mean change with 95% confidence intervals. Sample sizes: Better = 80, About the same = 22, Worse = 6. Minimally Important Difference (MID)
Fig. 3 Change in PROMIS scores from baseline to event visit by clinical disease status based on proteinuria remission status at event visit. All participants
were disease active at baseline. Remission was defied as normalization of urinary protein excretion and complete resolution of edema. Results are shown
as mean change with 95% confidence intervals. Sample sizes: Remission = 75, Active = 37. Minimally Important Difference (MID)
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As the care of children with chronic illnesses has im-
proved there has been a shift toward improving their
global care by fostering understanding of the impact of
disease on HRQOL. The PROMIS Pediatric measures
assess HRQOL in children between 8 and 17 years of
age. The PROMIS Pediatric measures have been vali-
dated in a number of childhood chronic illnesses includ-
ing cancer, asthma, obesity, chronic kidney disease, and NS
in the PROMIS I cross-sectional study [3, 15–17]. The
cross-sectional study of children with NS demonstrated
that the PROMIS Pediatric domains of Mobility, Pain Inter-
ference, Depressive Symptoms, Anxiety, and Peer Relation-
ships were associated with the clinical status of children
with chronic kidney disease [16]. In an analysis of the 151
children with nephrotic syndrome in the PROMIS I study,
children with active NS, defined by presence of edema, had
significantly worse scores in the domains of Mobility, Fa-
tigue, Pain Interference, and Anxiety when compared to
children with inactive nephrotic syndrome [3]. The results
of this study add to this growing literature and illustrate
that nephrotic syndrome appears to have a greater impact
on physical health domains (i.e., Mobility, Fatigue, Pain
Interference) than on mental or social domains.
These initial studies began to establish the feasibility
and validity of the PROMIS measures in children with
nephrotic syndrome. The current study takes a critical
step in extending the assessment of PROMIS measure
validation by assessing the responsiveness of the
Fig. 4 Change in PROMIS scores from baseline to month 12 visit. Participants were classified by proteinuria remission status at month 12. All participants
were disease active at baseline. Remission was defied as normalization of urinary protein excretion and complete resolution of edema. Results are shown
as mean change with 95% confidence intervals. Sample sizes: Remission = 49, Active = 41. Minimally Important Difference (MID)
Table 3 Correlation between changes in PRO domains
Peds QL Domains
PROMIS Domain Physical Functioning Emotional Functioning Social Functioning School Functioning Overall HRQOL
Physical Functioning
Mobility 0.60 0.39 0.45 0.37 0.60
Fatigue −0.65 −0.57 −0.48 −0.59 −0.73
Pain Interference −0.63 −0.52 −0.44 −0.46 −0.66
Emotional Functioning
Depressive Symptoms −0.46 −0.55 −0.44 −0.39 −0.57
Anxiety −0.51 −0.68 −0.35 −0.51 −0.64
Social Functioning
Peer Relationships 0.13 0.18 0.11 0.10 0.16
Estimates shown are Pearson correlation coefficients
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instrument to change in disease status over time. The
current study demonstrates that PROMIS measures are
capable of detecting significant changes over time that
correlate with global changes in the patients’ self-
reported disease status. In evaluating the clinical utility
of any measure, it is imperative to be able to interpret a
clinically meaningful change in a measured value, and to
do this clinicians and researchers may employ the con-
cept of minimally important difference in HRQOL mea-
sures. A minimally important difference is defined as the
“smallest difference in score … that patients perceive as
important, … and which would lead the clinician to con-
sider a change in the patient’s management” [14, 18–20].
A minimally important difference of 3 points in PRO-
MIS Pediatric measures has been defined for children
with nephrotic syndrome and other chronic health con-
ditions through research including patients, parent care-
givers, and physicians [14]. Based on this interpretation,
the PROMIS Mobility, Fatigue, Pain Interference, and
Anxiety measures were successful at detecting a greater
than a 3-point change related to the patients’ global as-
sessment of their nephrotic syndrome and of their over-
all health. We noted slightly stronger effect sizes for the
changes in global health than for the changes in neph-
rotic syndrome. This difference is not surprising as the
PROMIS domains are not disease specific, and may be
more responsive to overall changes in health than to dis-
ease specific changes.
A telling feature of these analyses is that, with few ex-
ceptions, the PROMIS domain score changes did not
distinguish between patients who achieved a proteinuric
remission and those with continued active disease on
follow up. At first glance, this may give clinicians pause
when assessing the utility of the instrument. One pos-
sible explanation for these findings is that generic PRO
domains may not adequately describe the nephrotic syn-
drome experience, and that perhaps a nephrotic
syndrome disease-specific domain, that uses terms and
content specific to nephrotic syndrome, may be needed.
Jolly et al., have recently published a novel disease-
specific instrument tailored to measure HRQOL in
patients with Systemic Lupus Erythematosus. Their val-
idation analyses revealed that that a greater amount of
variance in the disease specific HRQOL instrument was
explained by markers of disease activity and damage
than was found for the generic SF-36 instrument [21].
However, it is also important to consider that a patient’s
disease experience is defined by more than their clinical
markers of disease activity. Even though changes in
PROMIS domains did not correlate with changes in dis-
ease activity, we believe there is still value to measuring
a patient’s HRQOL in addition to their remission status
as these patient-assigned and clinician-assigned mea-
sures may provide complementary information. In
aggregate with our other analyses, we believe this study
provides evidence that these PROMIS domains are use-
ful tools in studying HRQOL in pediatric nephrotic syn-
drome patients.
As part of the validation of any new instrument such
as PROMIS, it is traditional to compare it to a validated
legacy measure (PedsQL) in a longitudinal population.
There is no validated HRQOL measure for children with
nephrotic syndrome. The PedsQL was selected as a leg-
acy measure for this study as it has been used in general
and disease focused research. We previously have shown
that the PROMIS measures and PedsQL provide similar
results in a number of domains with the strongest corre-
lations existing between the PedsQL emotional function-
ing domain and the PROMIS domains of Depressive
Symptoms and Anxiety in a cross-sectional analysis of
this cohort [11]. In contrast the weakest correlation was
between the social function and school functioning do-
mains in the PedsQL and the PROMIS Peer Relation-
ships domain. The current study confirms these findings
in a longitudinal analysis. Our longitudinal analyses re-
vealed significant and moderately strong correlations in
PROMIS Mobility, Fatigue, and Pain Interference with
the PedsQL Physical Functioning, as well as a significant
relationship between PROMIS Anxiety and PedsQL
Emotional Functioning. The longitudinal analyses also
identified no correlation between PROMIS Peer Rela-
tionships and PedsQL Social Functioning. This can be
partially explained by the domains assessing separate so-
cial constructs. The PROMIS Peer Relationship items
tend to reflect the quality of relationships (e.g., “My
friends and I helped each other out”) while the PedsQL
Social items test for problems getting along with others
(e.g., “Other kids do not want to be my friend”). We
show that the PROMIS and PedsQL provide comple-
mentary HRQOL information, but their imperfect corre-
lations indicate that there remain important differences
in the domains assessed by the instruments.
Although this study provides critical data about the re-
sponsiveness of the PROMIS measures in nephrotic syn-
drome, it is also important to acknowledge several study
limitations. The PROMIS Pediatric measures are limited
to ages 8–17 years. At the time of this study, only an
English version and school age self-report version of the
PROMIS Pediatric measures were available. Conse-
quently, the results of this study will be most applicable
to English language, school age children. Finally, the
study utilized the available PROMIS measure domains.
Since this study implementation there have been a num-
ber of new PROMIS domains developed that may also
capture important aspects of the nephrotic syndrome
disease experience. Future studies will benefit from pa-
tient participation in domain selection. Finally, it is
important to consider that none of the three types of
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anchors we used for validation, (1) self-reported global
assessment of change, (2) a clinical marker of disease
status, and (3) a legacy HRQOL instrument, are vali-
dated, gold-standard measures of HRQOL.
Conclusion
Patient-reported HRQOL measures are designed to
gather the patient perspective on their own health and
functional status. This study demonstrates that the
PROMIS Mobility, Fatigue, Pain Interference, and Anx-
iety domains are sensitive to self-reported changes in
disease and overall health status over time in children
with nephrotic syndrome. However, the PROMIS meas-
ure did not distinguish between groups of patients who
improved to clinical disease remission and patients who
remained with active disease. HRQOLs measure infor-
mation that is distinct from clinical laboratory assess-
ments and thus should be expected to provide
information that is complimentary to laboratory assess-
ments. The lack of significant anchoring to clinically de-
fined nephrotic syndrome disease active and remission
status may highlight an opportunity to improve the
measurement of HRQOL in children with nephrotic syn-
drome through the development of an additional neph-
rotic syndrome disease-specific HRQOL measure.
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